Patents by Inventor Susan M. Freier

Susan M. Freier has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10426789
    Abstract: The present embodiments provide methods, compounds, and compositions for treating, preventing, ameliorating, or slowing progression of retinitis pigmentosa (RP), such as autosomal dominant retinitis pigmentosa (AdRP) by administering a P23H rhodopsin specific inhibitor to a subject. The present embodiments provided herein are directed to compounds and compositions useful for treating, preventing, ameliorating, or slowing progression of retinitis pigmentosa (RP), such as autosomal dominant retinitis pigmentosa (AdRP). In certain embodiments, P23H rhodopsin inhibitors provided herein are allele-specific antisense compounds targeted to a P23H mutant allele that are capable of selectively inhibiting expression of P23H rhodopsin mutant protein to a greater extent than wild-type protein.
    Type: Grant
    Filed: February 26, 2016
    Date of Patent: October 1, 2019
    Inventors: Susan F. Murray, Punit P. Seth, Michael L. McCaleb, Susan M. Freier, Priyam Singh
  • Publication number: 20190276832
    Abstract: Provided herein are methods, compounds, and compositions for reducing expression of a DMPK mRNA and protein in an animal. Also provided herein are methods, compounds, and compositions for preferentially reducing CUGexp DMPK RNA, reducing myotonia or reducing spliceopathy in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate type 1 myotonic dystrophy, or a symptom thereof.
    Type: Application
    Filed: October 23, 2018
    Publication date: September 12, 2019
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Eric E. Swayze, Susan M. Freier
  • Publication number: 20190247420
    Abstract: Provided are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of ATXN3 mRNA in a cell or animal, and in certain instances reducing the amount of Ataxin-3 protein in a cell or animal. Such compounds, methods, and pharmaceutical compositions are useful to prevent or ameliorate at least one symptom or hallmark of a neurodegenerative disease. Such symptoms and hallmarks include ataxia, neuropathy, and aggregate formation. Such neurodegenerative diseases include SCA3.
    Type: Application
    Filed: November 10, 2017
    Publication date: August 15, 2019
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Susan M. Freier, Holly Kordasiewicz
  • Publication number: 20190249177
    Abstract: Provided herein are methods, compounds, and compositions for reducing expression of huntingtin mRNA and protein in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate Huntington's disease, or a symptom thereof.
    Type: Application
    Filed: February 8, 2019
    Publication date: August 15, 2019
    Inventors: Gene Hung, C. Frank Bennett, Susan M. Freier, Holly Kordasiewicz, Lisa Stanek, Don W. Cleveland, Seng H. Cheng, Lamya Shihabuddin
  • Publication number: 20190241896
    Abstract: The present embodiments provide methods, compounds, and compositions useful for inhibiting DNM2 expression, which may be useful for treating, preventing, or ameliorating a disease associated with DNM2.
    Type: Application
    Filed: January 15, 2019
    Publication date: August 8, 2019
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Susan M. Freier, Huynh-Hoa Bui, Susan F. Murray, Brett P. Monia, Shuling Guo
  • Publication number: 20190233827
    Abstract: Disclosed herein are antisense compounds and methods for decreasing PKK mRNA and protein expression. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate PKK-associated diseases, disorders, and conditions.
    Type: Application
    Filed: September 7, 2018
    Publication date: August 1, 2019
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Susan M. Freier, Huynh-Hoa Bui
  • Publication number: 20190225970
    Abstract: The present embodiments provide methods, compounds, and compositions for treating, preventing, or ameliorating a disease associated with excess growth hormone using antisense compounds or oligonucleotides targeted to growth hormone receptor (GHR).
    Type: Application
    Filed: December 27, 2018
    Publication date: July 25, 2019
    Inventors: Sanjay BHANOT, Susan M FREIER, Huynh-hoa BUI
  • Patent number: 10337007
    Abstract: The present invention provides oligomeric compounds. Certain such oligomeric compounds are useful for hybridizing to a complementary nucleic acid, including but not limited, to nucleic acids in a cell. In certain embodiments, hybridization results in modulation of the amount activity or expression of the target nucleic acid in a cell.
    Type: Grant
    Filed: January 26, 2018
    Date of Patent: July 2, 2019
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: Susan M. Freier, Eric E. Swayze
  • Publication number: 20190194666
    Abstract: Provided herein are methods, compounds, and compositions for reducing expression of GYS1 in an individual. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate a glycogen storage disease or disorder in an individual in need.
    Type: Application
    Filed: June 19, 2017
    Publication date: June 27, 2019
    Applicants: Ionis Pharmaceuticals, Inc., The Hospital for Sick Chlidren
    Inventors: Tamar R. Grossman, Susan M. Freier, Berge Minassian, Saija Ahonen
  • Publication number: 20190169613
    Abstract: Provided herein are methods, compounds, and compositions for reducing expression of transthyretin mRNA and protein in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate transthyretin amyloidosis, or a symptom thereof.
    Type: Application
    Filed: December 21, 2018
    Publication date: June 6, 2019
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Brett P. Monia, Susan M. Freier, Andrew M. Siwkowski, Shuling Guo
  • Publication number: 20190169610
    Abstract: The present invention provides oligomeric compounds. Certain such oligomeric compounds are useful for hybridizing to a complementary nucleic acid, including but not limited, to nucleic acids in a cell. In certain embodiments, hybridization results in modulation of the amount activity or expression of the target nucleic acid in a cell.
    Type: Application
    Filed: June 5, 2018
    Publication date: June 6, 2019
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Susan M. Freier, Eric E. Swayze
  • Patent number: 10308934
    Abstract: Disclosed herein are antisense compounds and methods for decreasing Ataxin 2 mRNA and protein expression. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate Ataxin 2 associated diseases, disorders, and conditions. Such Ataxin 2 associated diseases include spinocerebellar ataxia type 2 (SCA2), amyotropic sclerosis (ALS), and parkinsonism.
    Type: Grant
    Filed: March 19, 2015
    Date of Patent: June 4, 2019
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventor: Susan M. Freier
  • Publication number: 20190160090
    Abstract: Disclosed herein are compositions and compounds comprising modified oligonucleotides for modulating AGT and modulating a RAAS pathway related disease, disorder and/or condition in an individual in need thereof. A RAAS pathway related disease, disorder and/or condition in an individual such as hypertension can be treated, ameliorated, delayed or prevented with the administration of antisense compounds targeted to AGT.
    Type: Application
    Filed: October 7, 2016
    Publication date: May 30, 2019
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Adam Mullick, Mark J. Graham, Punit P. Seth, Susan M. Freier
  • Patent number: 10280423
    Abstract: The present embodiments provide methods, compounds, and compositions for treating, preventing, or ameliorating a disease associated with dysregulation of the complement alternative pathway by administering a Complement Factor B (CFB) specific inhibitor to a subject.
    Type: Grant
    Filed: May 1, 2015
    Date of Patent: May 7, 2019
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: Thazha P. Prakash, Punit P. Seth, Eric E. Swayze, Tamar R. Grossman, Michael L. McCaleb, Susan M. Freier
  • Publication number: 20190076465
    Abstract: The present embodiments provide methods, compounds, and compositions useful for inhibiting SMAD7 expression, which may be useful for treating, preventing, or ameliorating a disease associated with SMAD7.
    Type: Application
    Filed: September 7, 2018
    Publication date: March 14, 2019
    Inventors: Susan M. FREIER, Huynh-Hoa BUI
  • Publication number: 20190071677
    Abstract: Disclosed herein are antisense compounds and methods for decreasing LDL-C in an individual having elevated LDL-C. Additionally disclosed are antisense compounds and methods for treating, preventing, or ameliorating hypercholesterolemia and/or atherosclerosis. Further disclosed are antisense compounds and methods for decreasing coronary heart disease risk. Such methods include administering to an individual in need of treatment an antisense compound targeted to a PCSK9 nucleic acid. The antisense compounds administered include gapmer antisense oligonucleotides.
    Type: Application
    Filed: August 7, 2018
    Publication date: March 7, 2019
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Susan M. FREIER, Rosanne M. Crooke, Mark J. Graham, Kristina M. Lemonidis, Diane Tribble, Sanjay Bhanot, Andrew T. Watt
  • Patent number: 10221414
    Abstract: Disclosed herein are compositions and methods for reducing expression of C90RF72 mRNA and protein in an animal with C90RF72 specific inhibitors. Also disclosed herein are compositions and methods of selectively inhibiting a C90RF72 pathogenic associated mRNA variant by administering an antisense compound targeting the region beginning at the start site of exon 1A to the start site of exon 1B of a C90RF72 pre-mRNA. Such methods are useful to treat, prevent, or ameliorate neurodegenerative diseases in an individual in need thereof. Such C90RF72 specific inhibitors include antisense compounds.
    Type: Grant
    Filed: October 11, 2014
    Date of Patent: March 5, 2019
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: Susan M. Freier, Frank Rigo
  • Publication number: 20190062744
    Abstract: Compounds, compositions and methods are provided for modulating the expression and function of small non-coding RNAs. The compositions comprise oligomeric compounds, targeted to small non-coding RNAs. Methods of using these compounds for modulation of small non-coding RNAs as well as downstream targets of these RNAs and for diagnosis and treatment of disease associated with small non-coding RNAs are also provided.
    Type: Application
    Filed: September 6, 2018
    Publication date: February 28, 2019
    Applicant: Regulus Therapeutics Inc.
    Inventors: Christine Esau, Bridget Lollo, C. Frank Bennett, Susan M. Freier, Richard H. Griffey, Brenda F. Baker, Timothy A. Vickers, Eric G. Marcusson, Erich Koller, Eric E. Swayze, Ravi Jain, Balkrishen Bhat, Eigen Peralta
  • Publication number: 20190062755
    Abstract: Provided herein are methods, compounds, and compositions for reducing expression of an ANGPTL3 mRNA and protein in an animal. Also provided herein are methods, compounds, and compositions for reducing lipids and/or glucose in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate any one or more of cardiovascular disease and/or metabolic disease, or a symptom thereof, in an individual in need thereof.
    Type: Application
    Filed: September 7, 2018
    Publication date: February 28, 2019
    Inventors: Susan M. Freier, Mark J. Graham, Rosanne M. Crooke
  • Patent number: RE47320
    Abstract: Disclosed herein are antisense compounds and methods for decreasing CD40. Examples of disease conditions that can be ameliorated with the administration of antisense compounds targeted to CD40 include hyperproliferative disorders, graft versus host disease (GVHD), graft rejection, asthma, airway hyperresponsiveness, chronic obstructive pulmonary disease (COPD), multiple sclerosis (MS), systemic lupus erythematosus (SLE), and certain forms of arthritis.
    Type: Grant
    Filed: December 21, 2016
    Date of Patent: March 26, 2019
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: C. Frank Bennett, Lex M. Cowsert, Susan M. Freier